Clinicoepidemiological and microbiological evaluation of community-acquired ESBL Escherichia coli infections

Clinicoepidemiological and microbiological evaluation of community-acquired ESBL Escherichia coli infections - CA-ESBLEC_JAPAN study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051276

Enrollment

Registered

2023-06-07

Start date

2023-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections due to ESBL-E. coli

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 18 years and older Bacteriological diagnosis ESBL-producing E. coli detected in clinical specimens (case group) Non-ESBL-producing (3GCS: 3rd generation cephalosporin-susceptible) E. coli detected in clinical specimens within 3 days of admission or in outpatient setting (control group)

Exclusion criteria

Exclusion criteria: Cases deemed inappropriate for inclusion in the study by the principal investigator (e.g., significant missing medical record data)

Design outcomes

Primary

Measure	Time frame
1) Clinical-epidemiologic evaluation of community-onset ESBL E. coli infections and identification of risk factors 1) -1: Risk assessment of community-onset ESBL E. coli infection (comparison with community-onset 3GCS E. coli infection) Descriptive and univariate analysis of the clinical-epidemiologic characteristics of community-acquired ESBL-producing E. coli infections compared to susceptible strains will be conducted and independent risk factors for infection will be identified. 1)-2: Risk assessment of community-acquired ESBL E. coli infections (vs. nosocomial ESBL E. coli infections) Descriptive and univariate analyses to identify the clinico-epidemiologic characteristics of community-acquired ESBL E. coli infection compared to nosocomial infection will be conducted and independent risk factors for infection will be identified. 2) Evaluation of the association between molecular microbiological and clinical-epidemiological characteristics of ESBL E. coli infection. Descriptive and univariate analyses will be performed on molecular microbiological parameters to identify differences between community and nosocomial cases, the presence of nosocomial infection, and clinical epidemiological characteristics, as well as the presence or absence of spread of specific clones and geographic bias.	—

Measure

Time frame

1) Clinical-epidemiologic evaluation of community-onset ESBL E. coli infections and identification of risk factors 1) -1: Risk assessment of community-onset ESBL E. coli infection (comparison with community-onset 3GCS E. coli infection) Descriptive and univariate analysis of the clinical-epidemiologic characteristics of community-acquired ESBL-producing E. coli infections compared to susceptible strains will be conducted and independent risk factors for infection will be identified. 1)-2: Risk assessment of community-acquired ESBL E. coli infections (vs. nosocomial ESBL E. coli infections) Descriptive and univariate analyses to identify the clinico-epidemiologic characteristics of community-acquired ESBL E. coli infection compared to nosocomial infection will be conducted and independent risk factors for infection will be identified. 2) Evaluation of the association between molecular microbiological and clinical-epidemiological characteristics of ESBL E. coli infection. Descriptive and univariate analyses will be performed on molecular microbiological parameters to identify differences between community and nosocomial cases, the presence of nosocomial infection, and clinical epidemiological characteristics, as well as the presence or absence of spread of specific clones and geographic bias.

—

Countries

Japan

Contacts

Public ContactKayoko Hayakawa

National Center for Global Health and Medicine Department of Infectious Diseases/Disease Control and Prevention Center

khayakawa@hosp.ncgm.go.jp03-3202-7181

Outcome results